Tag Archives: Attorneys

Watch Jake Crosby’s AutismOne 2014 Talk

Props to AutismOne’s Teri Arranga for her introduction.

Originally posted on AutismOne

So often, when we think of investigating autism, we think of discovering the physiological underpinnings. But what about the sociological forces that perpetuate the autism epidemic? Politics from without? Or – surprisingly – politics from within? In this startling lecture, Jacob Crosby, MPH, discusses the obstructionist forces that have hampered progress within the autism advocacy arena.

Jake Crosby, MPH

Jake Crosby is editor of Autism Investigated. He is a 2011 graduate of Brandeis University with a bachelor’s degree in both history and health and a 2013 graduate of The George Washington University School of Public Health and Health Services with a master’s degree in epidemiology. He currently attends the University of Texas School of Public Health where he is studying for a PhD in epidemiology. For nearly five years, he was contributing editor to Age of Autism.

Originally posted at AutismOne

AutismOne is a non-profit charity organization 501(c)(3) started by a small group of parents of children with autism. Parents are and must remain the driving force of our community, the stakes are too high and the issues too sacred to delegate to outside interests. AUTISM IS A PREVENTABLE/TREATABLE BIOMEDICAL CONDITION. Autism is the result of environmental triggers. Autism is not caused by “bad” genes and the epidemic is not the result of “better” diagnosis. Children with autism suffer from gut bugs, allergies, heavy metal toxicity, mitochondrial disorders, antioxidant deficiencies, nutritional deficiencies and autoimmune diseases – all of which are treatable. THE KEY IS EDUCATION The AutismOne Conference, AutismOne Radio, AutismOne Outreach and Autism in Action initiatives educate more than 100,000 families every year about prevention, recovery, safety, and change.

Originally posted at AutismOne

 

Addendum: See AutismOne Slides

Mark Blaxill’s Thimerosal Backtrack: An Act To Throw The Omnibus?

actIIthecurtainpostomnibus

By Jake Crosby

Following the disclosure of emails on Autism Investigated in which Mark Blaxill responded to the lead omnibus attorney in vaccine court with attacks on expert witnesses Dr. Mark and David Geier, Autism Investigated reader John Best made an astute observation about the attorney’s email. Within that email, the attorney wrote:

“…we realize that we have to  deal with the fact that the increase has continued beyond the removal of thimerosal, but we have to convince the Special Masters that something in the environment, perhaps several somethings, is triggering symptoms of ASD in many kids.”

To which John Best responded in a comment:

“The lawyers claimed they had to account for the increase [in autism] after thimerosal was all gone and that they had to blame something in the environment. So, the lawyers admitted right there that they were throwing the case intentionally. Too bad the statute of limitations for legal malpractice has passed. Those words are all that are needed to hang them.
Did they think the whole world was too stupid to know that shooting 25 mcg of thimerosal into pregnant women equated to 200 times the alleged “safe” dose of mercury?
Jake, you should have entitled this: Lawyers Admit Throwing Case.”

To which I responded:

“That was almost certainly Mark Blaxill’s doing:
http://www.autisminvestigated.com/mark-blaxill-danish-fraudulent/

He claimed to change his views in a 2007 email to Dr. Brian Hooker based on the premature conclusion that reported autism prevalence still going up in California was evidence against thimerosal’s role in the autism epidemic, yet also cited the very Danish numbers Blaxill once called “uninformative and potentially misleading” to defend thimerosal right after being informed of their fraudulent nature by Dr. Hooker. What this would suggest is that Blaxill’s representation of himself as a leading proponent of thimerosal’s significance in causing the autism epidemic only to backtrack from his position later was all just an act to sink the omnibus and strike a PR victory for pharma.”

The latest component of this act that I did not mention in the above comment, however, is Blaxill’s downplaying of harm from thimerosal and vaccines in general. Neither was mentioned in Mark Blaxill’s speech before Congress, nor are they in the mission statement of the Canary Party that he chairs and founded. Such minimization of thimerosal’s harm helps prevent some of the worst perpetrators of the thimerosal cover-up from facing justice for burying evidence of its role in causing the autism epidemic. And the lead actor pretends to have no ties to the pharmaceutical industry when he still does.

It is about time someone drew the curtain on his act.

Jake Crosby is editor of Autism Investigated and is diagnosed with an autism spectrum disorder. He is a 2011 graduate of Brandeis University with a Bachelor of Arts in both History and Health: Science, Society and Policy and a 2013 graduate of The George Washington University School of Public Health and Health Services with a Master of Public Health in Epidemiology. He currently attends the University of Texas School of Public Health where he is studying for a Ph.D. in Epidemiology.

Mark Blaxill Remains Connected To BCG – A Pharma-Tied Consulting Firm

boston_consulting_group

By Jake Crosby

Revelations about Mark Blaxill’s ties to his former employer the Boston Consulting Group (BCG) and its pharmaceutical clients – in contradiction to what he said in a recently recorded interview on Linderman Unleashed – have now come to the attention of Autism Investigated. These discoveries were made on the heels of even more troubling evidence coming to light: see the previous post about Mark Blaxill turning the lead omnibus attorneys against expert witnesses Dr. Mark and David Geier with baseless and profane attacks against them.

In spite of Mark Blaxill claiming on Linderman Unleashed that he was fired from the BCG – suggesting his autism advocacy played a role – he appears to have voluntarily left the firm for the purpose of starting his own company and for reasons wholly unrelated to autism. In fact, Blaxill still maintains ties to BCG despite no longer being employed with the firm as Senior Vice President and despite claiming he no longer has a conflict of interest “of any kind.” Blaxill also falsely claimed to have always consulted for non-pharmaceutical clients while a BCG executive, merely admitting the firm had pharmaceutical clients but he in fact concealed from Linderman’s audience that he had consulted for Merck during his BCG employment.

Here’s the story he gave on his podcast interview with Curt Linderman, dated October 24, 2013, regarding his BCG departure:

“And then in 2006 – early in 2006 not very long after Evidence of Harm came out – all of a sudden I found myself without a job, and I was no longer at the Boston Consulting Group…I did have issues that concerned me, and it actually didn’t stop me from speaking out, Curt, but it did worry me a little, and who knows? Maybe my worries were founded because I’m not working there anymore, and that was not my choice.”

However, the book Lords of Strategy: The Secret Intellectual History of the New Corporate World by Walter Kiechel tells a story about Mark Blaxill’s departure from Boston Consulting Group (BCG) that totally contradicts what Blaxill told Linderman. According to Kiechel:

“Blaxill wanted to push on to the issue of motivation, of why people worked on Linux for free, even into issues of creativity, but couldn’t find the time or support within the firm for exploring those dimensions. “The antibodies resisted that,” he says. In 2006, Blaxill left BCG to set up his own firm, 3LP Advisors, to concentrate on the intersection of strategy, intellectual property, and innovation.”  

In his interview on Linderman, Blaxill said 3LP Advisors was founded as a result of his firing from Boston Consulting Group, claiming the termination of his employment “was not my choice.” Yet not only was it his choice according to Kiechel, but in fact Blaxill left Boston Consulting Group so that he could found 3LP Advisors to practice his own business strategy the way he liked – nothing to do with autism.

Linderman then further questioned Blaxill specifically about his conflict of interest with Boston Consulting Group since 2006:

“To me it would seem as if you were still with this company and you still had this conflict of interest, and that is not the case since 2006?”

To which Blaxill replied by emphatically denying possession of any conflict of interest:

“Curt, I don’t have a conflict of interest of any kind now, and I have not had one for years. I haven’t had a conflict since I started the Age of Autism with JB Handley and Dan Olmsted and Kim Stagliano back in 2007. I haven’t had a conflict since I wrote the book The Age of Autism. I haven’t had a conflict since starting the Canary Party. The only time I had a conflict was when I was helping David Kirby and contributing to the Evidence of Harm book. And it’s even in the book, Curt; I have never hid the conflict. I’ve actually been public with people and open with people about the concerns I’ve had. So it’s not as though there is any great secrets I was keeping. And whatever concern I had, it is not operative any longer.”

However, Blaxill remains a board member of the Initiative for a Competitive Inner City (ICIC), which has received over $25,000 annually from Boston Consulting Group. Serving on the board with him is none other than Boston Consulting Group’s Chairman of the Board Carl Stern.

ICIC’s chairman and founder as well as Harvard Business School Prof. Michael Porter was thanked in no uncertain terms in the acknowledgements section of the book Blaxill coauthored in 2009 with his business partner Ralph Eckardt, “The Invisible Edge: Taking Your Strategy to the Next Level Using Intellectual Property:

“[The Boston Consulting Group Founder’s] ideas have been extended and enriched by the academic and consulting community in Boston, most notably by Harvard Business School Professor Michael Porter, on one hand, and our former colleagues at BCG on another.”

Blaxill and Eckardt then summed up their relationship with Prof. Porter as follows:

“Michael Porter has been a teacher, a collaborator, a client, and a friend.” 

It seems Blaxill and Eckardt are not the only ones with high praise for Prof. Porter. When Porter was awarded a prestigious University Professorship at Harvard, Merck’s then-chairman, president and CEO Raymond Gilmartin (who later resigned over the Vioxx scandal and became a Harvard Business School Professor himself) told the Harvard Gazette:

“Through his research, teaching, and writing, Mike Porter has made an indelible mark on businesses and markets everywhere. His leading-edge research has directly influenced the strategies and competitiveness of individual firms and the nation. More recently, he has helped to identify the key drivers of innovation, which has now become the basis of global competition. His insights are directly relevant to understanding the vital ingredients for success in a host of industries, including pharmaceuticals.”

Clearly Blaxill has much to gain by serving on ICIC’s board of directors with his former employer BCG’s Chairman of the Board while under Prof. Porter’s chairmanship. ICIC’s website boasts that the organization’s partners “gain as well as give.” It’s hard to fathom how Blaxill could honestly claim on Linderman to not possess a conflict of interest “of any kind.”

But Blaxill was not even honest in the Linderman interview about what he did during his past employment for BCG. He claimed:

“…I always worked with industrial companies, automotive, forest products, computers-type companies, but they also had pharmaceutical clients.”

But he did not solely work with those companies, because Blaxill consulted for Merck directly as a BCG employee himself. In 2010, he told me he had visited Merck’s headquarters in Whitehouse Station, New Jersey. Later at a 2011 gathering in Waltham, Massachusetts, where Blaxill announced his preliminary plans to found the Canary Party – I overheard him telling someone about his experience consulting for Merck, describing his former clients as “not that smart.”

Despite suggesting his departure from Boston Consulting Group was some sort of martyrdom for his autism advocacy and that he no longer has any ties to the firm, it appears that Mark Blaxill was not fired, but left on his own terms wholly unrelated to autism and even remains connected to his former employer who continues to serve pharmaceutical clients.

Jake Crosby is editor of Autism Investigated and is diagnosed with an autism spectrum disorder. He is a 2011 graduate of Brandeis University with a Bachelor of Arts in both History and Health: Science, Society and Policy and a 2013 graduate of The George Washington University School of Public Health and Health Services with a Master of Public Health in Epidemiology. He currently attends the University of Texas School of Public Health where he is studying for a Ph.D. in Epidemiology.

Mark Blaxill to Omnibus Attorneys: “how deeply f*cked up the world is when the Geiers are considered credible analysts and I am not.”

blaxillongeiers

By Jake Crosby

Click the above screenshot to enlarge the July 2007 email where then-Vice President of SafeMinds Mark Blaxill stated in email to omnibus autism proceeding attorneys Mike Williams and Tom Powers concerning petitioners’ expert witnesses Dr. Mark and David Geier:

“I hope you understand how deeply fucked up the world is when the Geiers are considered credible analysts and I am not.”

Blaxill succeeded in turning Williams against his own expert witnesses, as Williams responded: “I do understand”.

Autism Investigated has acquired this latest installment of troubling emails about the Geiers between Blaxill and Williams from a source that wishes to remain anonymous. Last October, Autism Investigated posted emails dated 2003-2004 in which Mark Blaxill disparaged expert witnesses Dr. Mark and David Geier to Mike Williams – saying the Geiers “can do our cause more harm than good,” calling their work “sloppy” and claiming he could “rip [their work] to shreds.” Those emails were also obtained from a confidential source. (See mercury toxicity expert Dr. Boyd Haley’s response to Blaxill’s claim.)

The long email from Mike Williams to which Blaxill was responding can be seen in the following screenshot and was addressed to Lyn Redwood, President of SafeMinds (now Vice President of SafeMinds). Copied on the email in addition to Blaxill were Tom Powers and SafeMinds’ then-Executive Director (now President) Sallie Bernard. Note also that Williams described pursuit of “experts other than Mark Geier” before lamenting, “if only Mark Blaxill had an MPH or equivalent.” (screenshot 1, click to enlarge)
fdup2

Further down in that email, Williams reveals how influenced he was by Blaxill, saying: “On the genetics issue, we need someone other than Mark Geier to say what Mark Blaxill and you all proved…” (screenshot 2, click to enlarge) Incredibly, Williams was persuaded that Dr. Geier, a geneticist, was incapable of speaking on the genetics issue even though his genetic research had won him presidential recognition. What’s more, his son David actually discovered results from CDC researcher Dr. Thomas Verstraeten’s epidemiological analyses of thimerosal exposure showing vastly increased risks for neurodevelopmental disorders including autism compared to those who weren’t exposed to thimerosal during the first month of life. That a seasoned attorney was so manipulated by Mark Blaxill should serve as a cautionary tale in light of current events.

fdup3
fdup4

Jake Crosby is editor of Autism Investigated and is diagnosed with an autism spectrum disorder. He is a 2011 graduate of Brandeis University with a Bachelor of Arts in both History and Health: Science, Society and Policy and a 2013 graduate of The George Washington University School of Public Health and Health Services with a Master of Public Health in Epidemiology. He currently attends the University of Texas School of Public Health where he is studying for a Ph.D. in Epidemiology.